Epizyme Outlines Clinical Progress, TAZVERIK Development Strategy and Pipeline Priorities During Company's Strategic Vision CallBusiness Wire • 03/02/21
Epizyme's (EPZM) CEO Rob Bazemore on Q4 2020 Results - Earnings Call TranscriptSeeking Alpha • 02/23/21
CORRECTING and REPLACING Epizyme Provides Business Update and Reports Fourth Quarter and Full Year 2020 Financial ResultsBusiness Wire • 02/23/21
Epizyme Provides Business Update and Reports Fourth Quarter and Full Year 2020 Financial ResultsBusiness Wire • 02/23/21
Epizyme Announces Date of Fourth Quarter and Full Year 2020 Financial Results and Participation in Upcoming Investor ConferencesBusiness Wire • 02/16/21
Epizyme (EPZM) Down 3.4% Since Last Earnings Report: Can It Rebound?Zacks Investment Research • 12/06/20
Epizyme, Inc. (EPZM) CEO Robert Bazemore on Q3 2020 Results - Earnings Call TranscriptSeeking Alpha • 11/06/20
Epizyme Announces Expanded Loan Facility with Pharmakon Advisors for Additional $150 Million to Fund its Growth InitiativesBusiness Wire • 11/06/20
Epizyme Announces Two Lancet Oncology Publications on TAZVERIK® (tazemetostat) Phase 2 Data in Epithelioid Sarcoma and Follicular LymphomaBusiness Wire • 10/07/20
Epizyme to Participate in Morgan Stanley 18th Annual Global Healthcare ConferenceBusiness Wire • 09/08/20
Epizyme's (EPZM) CEO Rob Bazemore on Q2 2020 Results - Earnings Call TranscriptSeeking Alpha • 08/04/20
Epizyme Announces Date of Second Quarter 2020 Financial Results and Participation at 2020 Wedbush PacGrow Healthcare Virtual ConferenceBusiness Wire • 07/28/20